Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)

Catherine J. Mummery; Anne Börjesson-Hanson; Daniel J. Blackburn; Everard G. B. Vijverberg; Peter Paul de Deyn; Simon Ducharme; Michael Jonsson; Anja Schneider; Juha O. Rinne; Albert C. Ludolph; Ralf Bodenschatz; Holly Kordasiewicz; Eric E. Swayze; Bethany Fitzsimmons; Laurence Mignon; Katrina M. Moore; Chris Yun; Tiffany Baumann; Dan Li; Daniel A. Norris; Rebecca Crean; Danielle L. Graham; Ellen Huang; Elena Ratti; C. Frank Bennett; Candice Junge; Roger M. Lane

doi:https://doi.org/10.1038/s41591-023-02639-3

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)

Catherine J. Mummery, Anne Börjesson-Hanson, Daniel J. Blackburn, Everard G. B. Vijverberg, Peter Paul de Deyn, Simon Ducharme, Michael Jonsson, Anja Schneider, Juha O. Rinne, Albert C. Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E. Swayze, Bethany Fitzsimmons, Laurence Mignon, Katrina M. Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A. NorrisRebecca Crean, Danielle L. Graham, Ellen Huang, Elena Ratti, C. Frank Bennett, Candice Junge, Roger M. Lane

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

Correction to: Nature Medicine. Published online 24 April 2023. In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read “Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK” in the HTML and PDF versions of the article.

Original language	English
Journal	Nature medicine
Early online date	2023
DOIs	https://doi.org/10.1038/s41591-023-02639-3
Publication status	E-pub ahead of print - 2023

Access to Document

https://doi.org/10.1038/s41591-023-02639-3

Cite this

Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., de Deyn, P. P., Ducharme, S., Jonsson, M., Schneider, A., Rinne, J. O., Ludolph, A. C., Bodenschatz, R., Kordasiewicz, H., Swayze, E. E., Fitzsimmons, B., Mignon, L., Moore, K. M., Yun, C., Baumann, T., Li, D., ... Lane, R. M. (2023). Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3). Nature medicine. Advance online publication. https://doi.org/10.1038/s41591-023-02639-3

@article{d456f469eaee432da9b598d57b4816ab,

title = "Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer{\textquoteright}s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)",

abstract = "Correction to: Nature Medicine. Published online 24 April 2023. In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read “Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK” in the HTML and PDF versions of the article.",

author = "Mummery, {Catherine J.} and Anne B{\"o}rjesson-Hanson and Blackburn, {Daniel J.} and Vijverberg, {Everard G. B.} and {de Deyn}, {Peter Paul} and Simon Ducharme and Michael Jonsson and Anja Schneider and Rinne, {Juha O.} and Ludolph, {Albert C.} and Ralf Bodenschatz and Holly Kordasiewicz and Swayze, {Eric E.} and Bethany Fitzsimmons and Laurence Mignon and Moore, {Katrina M.} and Chris Yun and Tiffany Baumann and Dan Li and Norris, {Daniel A.} and Rebecca Crean and Graham, {Danielle L.} and Ellen Huang and Elena Ratti and Bennett, {C. Frank} and Candice Junge and Lane, {Roger M.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

doi = "https://doi.org/10.1038/s41591-023-02639-3",

language = "English",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

}

Mummery, CJ, Börjesson-Hanson, A, Blackburn, DJ, Vijverberg, EGB, de Deyn, PP, Ducharme, S, Jonsson, M, Schneider, A, Rinne, JO, Ludolph, AC, Bodenschatz, R, Kordasiewicz, H, Swayze, EE, Fitzsimmons, B, Mignon, L, Moore, KM, Yun, C, Baumann, T, Li, D, Norris, DA, Crean, R, Graham, DL, Huang, E, Ratti, E, Bennett, CF, Junge, C & Lane, RM 2023, 'Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)', Nature medicine. https://doi.org/10.1038/s41591-023-02639-3

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3). / Mummery, Catherine J.; Börjesson-Hanson, Anne; Blackburn, Daniel J. et al.
In: Nature medicine, 2023.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Author Correction

T2 - Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)

AU - Mummery, Catherine J.

AU - Börjesson-Hanson, Anne

AU - Blackburn, Daniel J.

AU - Vijverberg, Everard G. B.

AU - de Deyn, Peter Paul

AU - Ducharme, Simon

AU - Jonsson, Michael

AU - Schneider, Anja

AU - Rinne, Juha O.

AU - Ludolph, Albert C.

AU - Bodenschatz, Ralf

AU - Kordasiewicz, Holly

AU - Swayze, Eric E.

AU - Fitzsimmons, Bethany

AU - Mignon, Laurence

AU - Moore, Katrina M.

AU - Yun, Chris

AU - Baumann, Tiffany

AU - Li, Dan

AU - Norris, Daniel A.

AU - Crean, Rebecca

AU - Graham, Danielle L.

AU - Huang, Ellen

AU - Ratti, Elena

AU - Bennett, C. Frank

AU - Junge, Candice

AU - Lane, Roger M.

PY - 2023

Y1 - 2023

N2 - Correction to: Nature Medicine. Published online 24 April 2023. In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read “Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK” in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicine. Published online 24 April 2023. In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read “Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK” in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85174321210&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41591-023-02639-3

DO - https://doi.org/10.1038/s41591-023-02639-3

M3 - Comment/Letter to the editor

C2 - 37845513

SN - 1078-8956

JO - Nature medicine

JF - Nature medicine

ER -

Mummery CJ, Börjesson-Hanson A, Blackburn DJ, Vijverberg EGB, de Deyn PP, Ducharme S et al. Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3). Nature medicine. 2023. Epub 2023. doi: https://doi.org/10.1038/s41591-023-02639-3

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)

Abstract

Access to Document

Other files and links

Cite this